Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
  • Platform
  • Pipeline
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Connect

Press Releases

To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis"  Click Here

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Apr 19, 2022

ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

Apr 7, 2022

ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

Apr 7, 2022

ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders

Mar 24, 2022

ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

Mar 22, 2022

ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Mar 17, 2022

ProMIS Neurosciences Announces Fiscal Year 2021 Results

Mar 10, 2022

ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders

Mar 2, 2022

ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease

Feb 3, 2022

ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board

Jan 27, 2022

ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board

  • arrow_back
  • 1…
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • …27
  • arrow_forward
Linkedin Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy

Disclaimer

All statements and expressions are the sole opinion of the company and are subject to change without notice.  The Company is not liable for any investment decisions by its readers or subscribers.  It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies.  The information contained herein has been provided as an information service only.  The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.  Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements".  Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.